Treatment of Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).
Most trials reported today are in metastatic TNBC, but areas that need more attention are HER2+ disease and hormone-refractory hormone-receptor positive breast cancer, said Nanda. Knowledge of the role of immune checkpoint inhibition within these subtypes of breast cancer is needed as well.
Nanda is also hoping combination therapy with immune checkpoint inhibitors, vaccines, and other therapies will help to improve the current response rates.
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
